| Mutation Could Aid Tourette Research A rare genetic mutation may open a new avenue for treating Tourette syndrome, researchers reported. online.wsj.com |
First Joint Health Assessment - Video Orthopaedic surgeon and founder of the San Francisco-based Joint Health Beverage Company creates a web-based tool that assesses the condition of joints and provides tips on improving joint health feedproxy.google.com |
Doctors Fight Cosmetic Foot Surgery Toe shortening, toe lengthening and injections into the pads of the feet are among cosmetic foot procedures blasted by the American Orthopaedic Foot and Ankle Society. online.wsj.com |
Biodel's Linjeta Should Overcome the Usual FDA Approval Hurdles Joseph Krueger submits: Previously, I wrote an article about Biodel's (BIOD) VIAject (now called Linjeta), comparing its benefits to Mannkind’s (NASDAQ: MNKD) Afrezza. Linjeta is a more rapid-acting form of injectable human insulin for meal-time use by patients with Type 1 or Type 2 diabetes. Linjeta provides quicker glucose control than standard insulin, and also touts the benefits of reducing the usual weight gain and life-threatening hypoglycemic events seen in insulin users. Current insulin therapies are not delivered quickly enough to simulate the desired meal-time insulin spike. The formulation of insulin in Linjeta promotes a more rapid absorption, which more closely mirrors the effects of naturally produced insulin in non-diabetics, thereby providing more effective blood glucose control. In the article I discussed the potential problems facing Mannkind’s Afrezza approval and compared it to VIAject/Linjeta's potential approval. In the face of several recent panel reviews and/or FDA approvals having a poor outcome, I thought it would be a good time to re-visit this idea and discuss the prospects for Linjeta’s approval in light of several developments.Complete Story » seekingalpha.com |
Bottom Fishing: Any Value in September's Losers? StreetAuthority submits: by David StermanWith reward comes risk. That's the painful lesson learned by biotech investors last month. Investors in Arena Pharma (Nasdaq: ARNA), Idenix Pharma (Nasdaq: IDIX), AMAG Pharma (Nasdaq: AMAG) and Vical (Nasdaq: VICL) all saw their investments plunge by nearly a fourth-- or more -- thanks to bad news on the drug approval front. Of the top four losers in the Russell 2000 last month, all are in biotech -- an industry for which you've got to have a strong stomach.Complete Story » seekingalpha.com |